8-K: Zymeworks Halts ZW171 Cancer Drug Development

Zymeworks Inc. announced the voluntary discontinuation of clinical development for its T cell engager ZW171, citing an unfavorable benefit-risk profile.

Summary

• Zymeworks Inc. has voluntarily discontinued the clinical development of ZW171, a T cell engager designed to target gynecological, thoracic, and digestive system cancers.
• The decision was based on the completion of planned dose escalation cohorts in a Phase 1 trial for patients with ovarian cancer and non-small cell lung cancer.
• After establishing a maximum tolerated dose, the company determined that further dose evaluation would be unlikely to support a benefit-risk profile consistent with the desired monotherapy target product profile.
• Dose-limiting toxicities consistent with mesothelin-related on-target off-tumor toxicity were observed, although cytokine release syndrome was well-managed.
• Ongoing participants in the Phase 1 trial will continue treatment at the discretion of their investigator, and those who have discontinued will continue safety follow-up.
• Zymeworks continues to advance its broader product pipeline, including the ongoing Phase 1 trial of ZW191 and the expected initiation of a Phase 1 study for ZW251 in 2025.
• An Investigational New Drug (IND) filing for ZW209, a DLL3-directed trispecific T cell engager, is planned for the first half of 2026.
• Zanidatamab, a HER2-targeted bispecific antibody developed by Zymeworks, has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

Sentiment

Score: 4

Explanation: The discontinuation of a clinical program is a significant negative event, reflecting a failure to meet desired efficacy/safety profiles. However, the company's proactive decision-making, disciplined portfolio management, and continued progress with other pipeline assets (including an already approved product, zanidatamab) mitigate the overall negative impact, preventing a lower score.

Positives

• Zymeworks maintains a disciplined approach to product portfolio management, focusing resources on candidates with the greatest potential impact for patients.
• The company continues to advance a broader product pipeline, including ZW191 (Phase 1 ongoing) and ZW251 (Phase 1 expected in 2025).
• An IND filing for ZW209, a DLL3-directed trispecific T cell engager, is planned for the first half of 2026.
• Zanidatamab, developed using Zymeworks' proprietary Azymetric technology, has received accelerated approvals in the U.S., China, and Europe for HER2-positive biliary tract cancer, marking it as the first and only dual HER2-targeted bispecific antibody approved for this indication in these regions.

Negatives

• Voluntary discontinuation of clinical development for ZW171, a T cell engager targeting gynecological, thoracic, and digestive system cancers.
• The decision was based on an unfavorable benefit-risk profile after establishing a maximum tolerated dose in a Phase 1 trial.
• Dose-limiting toxicities consistent with mesothelin-related on-target off-tumor toxicity were observed during the Phase 1 study.

Risks

• Any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable.
• Zymeworks may not achieve milestones or receive additional payments under its collaborations.
• Regulatory agencies may impose additional requirements or delay the initiation of clinical trials.
• The impact of new or changing laws and regulations.
• Market conditions.
• The impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors.
• Zanidatamab may not be successfully commercialized.
• Zymeworks' evolution of its business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented.
• Clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates.
• Zymeworks' assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect.
• Inability to maintain or enter into new partnerships or strategic collaborations.

Future Outlook

Zymeworks plans to continue advancing its broader product pipeline, including the ongoing Phase 1 trial of ZW191 and the expected initiation of a Phase 1 study for ZW251 in 2025. An IND filing for ZW209, a DLL3-directed trispecific T cell engager, is planned for the first half of 2026. The company also highlights the accelerated approvals of zanidatamab in the U.S., China, and Europe for HER2-positive biliary tract cancer, positioning it as a key asset.

Management Comments

• "While this is a disappointing outcome given the promising preclinical activity observed with ZW171, we are deeply grateful to the patients, providers, and caregivers for their support and participation in the ZW171 Phase 1 study." Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
• "As part of Zymeworks disciplined approach to the management of our broad product portfolio, we are committed to careful and consistent evaluation of clinical progress for each product candidate to ensure our resources are directed towards those product candidates with the greatest potential impact for patients." Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.

Industry Context

The discontinuation of ZW171 highlights the inherent high-risk nature of early-stage drug development in oncology, particularly with novel T cell engagers targeting challenging antigens like mesothelin. While a setback for this specific program, Zymeworks' strategic decision to reallocate resources to other promising pipeline assets (ZW191, ZW251, ZW209) and its success with zanidatamab in HER2-positive cancers demonstrates a common industry practice of portfolio optimization to manage risk and maximize return on investment in a competitive biopharmaceutical landscape.

Stakeholder Impact

• Shareholders: Potential negative impact due to the failure of a pipeline asset, but mitigated by the company's disciplined approach and focus on other promising programs.
• Patients: Patients currently on ZW171 may continue treatment, but future patients will not have this option. The company expressed gratitude to participants in the trial.
• Employees: Potential reallocation of resources and personnel from the ZW171 program to other pipeline projects.

Next Steps

• Ongoing participants in the ZW171 Phase 1 trial will continue treatment at the discretion of their investigator.
• Participants who have discontinued ZW171 treatment will continue safety follow-up as per the study protocol.
• Continue advancing the Phase 1 trial of ZW191.
• Initiate a Phase 1 study for ZW251 in 2025.
• Prepare an IND filing for ZW209, a DLL3-directed trispecific T cell engager, planned in the first half of 2026.

Key Dates

Recommendation

While the discontinuation of a clinical program is a negative event, Zymeworks' proactive decision-making and strategic reallocation of resources to a broader pipeline, including an already approved product (zanidatamab) and several other promising candidates, suggest a disciplined approach to R&D. The company's ability to manage risk and focus on assets with higher potential warrants a 'hold' recommendation, as the long-term outlook depends on the success of these other programs, which are still in early stages. Investors should monitor the progress of ZW191, ZW251, and ZW209, and the commercial performance of zanidatamab.

Keywords

Zymeworks, ZW171, clinical development, discontinuation, T cell engager, cancer, oncology, biotechnology, Phase 1 trial, mesothelin, ZW191, ZW251, ZW209, zanidatamab, HER2, biliary tract cancer, biotherapeutics